Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03148808
Other study ID # Protocol No.: 1060-001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 25, 2017
Est. completion date October 29, 2018

Study information

Verified date November 2018
Source Alucent Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The NVS Therapy is being studied to evaluate the safety and efficacy of retention of acute luminal gain, leading to acute hemodynamic improvement in superficial femoral and popliteal arteries with reference vessel diameters between 3.5 and 7.0 mm and lesion lengths between 36 and 96mm. The system is intended for use in patients with de novo lesions in the superficial femoral and proximal popliteal arteries.


Description:

This is a prospective, non-randomized, multi-center, open label Phase 1 study to assess the safety, pharmacokinetics (PK), and preliminary efficacy trends of applying NVS Therapy to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during percutaneous transluminal angioplasty (PTA) in patients with life-style limiting claudication due to obstructive SFA and proximal popliteal artery atherosclerosis. Each investigator will receive supervised training for each procedure.

Eligibility to participate in the study is determined during the screening period and prior to the index procedure. Once a subject has been determined to be suitable for a peripheral intervention and all general eligibility criteria are met, angiographic eligibility will be evaluated at the time of the index procedure. Subjects then undergo the procedure with the NVS Therapy. Study data will be analyzed through the Day 365 follow-up visit.


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date October 29, 2018
Est. primary completion date October 29, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subject is at least 18 years of age.

- Subject (or legal guardian) understands the study requirements and the treatment procedure and provides written informed consent before any study-specific tests or procedures are performed.

- Subject is eligible for PTA.

- Subject is willing to comply with all protocol required follow-up evaluations.

- Subject has documented Rutherford Classification 2 to 4 (see Appendix 3).

- Subject has laboratory test results that are within clinically acceptable limits.

- In Investigator's opinion, subject is hemodynamically stable at the time of the index procedure.

- Subject has a life expectancy of =1 year in the opinion of the Investigator.

Exclusion Criteria:

- Subject had cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 3 months prior to enrollment.

- Subject has any permanent neurologic defect that may cause non-compliance with the protocol.

- Subject had an MI within last the 3 months prior to enrollment.

- Subject is pregnant, planning to become pregnant, breastfeeding or planning to breastfeed in the next 365 days.

- Subject is currently receiving oral or intravenous immunosuppressive therapy (ie, inhaled steroids are not excluded).

- Subject has known life-limiting immunosuppressive or autoimmune disease (eg, human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus).

- Subject has local or systemic thrombolytic therapy within 48 hours prior to index procedure.

- Subject is currently on oral anticoagulation therapy, such as warfarin, rivaroxaban, apixaban, or dabigatran etexilate.

- Subject has known allergies or sensitivities to heparin, aspirin (ASA), or other anticoagulant/antiplatelet therapies.

- Subject has an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure.

- Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding.

- Subject has documented or suspected liver disease, including laboratory evidence of hepatitis.

- Subject has renal failure or chronic kidney disease with glomerular filtration rate (GFR) = 30 mL/min or Modification of Diet in Renal Disease (MDRD) study equation result of = 30 mL/min per 1.73 m2.

- Subject has white blood cell (WBC) count < (3,000 cells/mm3) within 7 days prior to index procedure.

- Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3 = 7 days pre-procedure.

- Subject has been diagnosed with bleeding diatheses or hypercoagulable state.

- Subject has known or suspected active systemic infection evidenced by WBC > 14.0 (14,000/mm3).

- Subject is currently participating in another investigational drug or device study.

- Subject intends to participate in another investigational drug or device study within 365 days after the index procedure.

- Subject has any surgical procedure or intervention performed within the 30-day period prior to index procedure.

Study Design


Intervention

Combination Product:
NVS Therapy
Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS Light Fiber, and NVS Light Source.

Locations

Country Name City State
United States OhioHealth Research Institute Columbus Ohio
United States Wellmont CVA Heart Institute Kingsport Tennessee
United States Lankenau Institute for Medical Research Wynnewood Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Alucent Medical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other NVS Drug Plasma Concentrations The Peak Plasma Concentration (Cmax) will be determined from plasma 10-8-10 Dimer concentrations for blood samples collected. Day 1
Primary Freedom from all-cause mortality, target limb major amputation, and target lesion revascularization based on clinical observations The overall composite occurrence of participants free from from all-cause mortality, target limb major amputation, and target lesion revascularization through post-index procedure to Day 30 will be summarized as a percentage. Day 30
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1